Bender Robert & Associates Sells 7,476 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bender Robert & Associates decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 72.1% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,887 shares of the biopharmaceutical company's stock after selling 7,476 shares during the period. Bender Robert & Associates' holdings in Gilead Sciences were worth $323,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in GILD. Annis Gardner Whiting Capital Advisors LLC lifted its stake in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the period. Morton Brown Family Wealth LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth about $35,000. Whipplewood Advisors LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $35,000. Synergy Investment Management LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at about $40,000. Finally, Lee Danner & Bass Inc. bought a new position in Gilead Sciences in the fourth quarter worth about $41,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Bank of America lifted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $110.55.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now owns 168,174 shares of the company's stock, valued at $17,893,713.60. This trade represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,500 shares of company stock worth $5,236,245. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Down 2.6%

GILD stock opened at $108.00 on Wednesday. The stock has a market capitalization of $134.34 billion, a P/E ratio of 22.74, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences, Inc. has a 1-year low of $62.69 and a 1-year high of $119.96. The business has a fifty day moving average price of $105.88 and a 200-day moving average price of $102.49.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences's revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.32) EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.93%. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.